MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2024 International Congress

    A matching-adjusted indirect comparison of efficacy and safety for safinamide versus rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease

    Y. Tan, Q. Wei, P. Xu, E. Tao, L. Wang, C. Cattaneo, H. Shang, S. Chen (Shanghai, China)

    Objective: To compare  efficacy and safety of safinamide and rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease (PD) by matching-adjusted indirect…
  • 2024 International Congress

    Combining Carbidopa/levodopa Extended-release Capsules and Immediate-release Tablets – Crucial Factors of This Economical Prescription

    Y. Tai, S. Hsu, H. Kuo (Kaohsiung City, Taiwan)

    Objective: We introduced a new way of prescribing carbidopa/levodopa extended-release (ER) capsule – combining use of immediate-release (IR) tablets. This retrospective clinical study was designed…
  • 2024 International Congress

    Long-term Safety and Efficacy for Motor Fluctuations and Quality of Life With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease: Interim Results From an Ongoing Open Label Extension

    F. Bergquist, J. Aldred, C. Carroll, E. Danielsen, M. Facheris, R. Gupta, A. Jeong, A. Spiegel, V. Fung (Mölndal, Sweden)

    Objective: Evaluate long-term motor symptom control and improvement in quality of life (QoL) with foslevodopa/foscarbidopa (LDp/CDp) compared with baseline (BL) values from the parent study…
  • 2024 International Congress

    One dose fits all? An analysis of the levodopa equivalent dose over time in Parkinson’s disease

    V. Lavu, J. Dwarampudi, Q. Yuan, F. Sarmento, T. de Araujo, V. Garg, J. Wong (Gainesville, USA)

    Objective: To ascertain and delineate the differences in Levodopa Equivalent Dose (LEDD) among Parkinson’s disease (PD) subtypes and to examine its evolution over the disease’s…
  • 2024 International Congress

    AI for Personalized Medication Management in Parkinson’s Disease

    R. Diaz-Rincon, H. Khoshbouei, B. Shickel (Gainesville, USA)

    Objective: To assess medication usage over time in Parkinson’s Disease utilizing AI in EHR data. Background: Parkinson's disease (PD) is a complex neurodegenerative disorder characterized…
  • 2024 International Congress

    A Comparative Bioavailability Study between a Marketed Capsule-based Levodopa Dry Powder Inhaler and a New Pre-filled Levodopa Dry Powder Inhaler

    T. van Laar, F. Grasmeijer, M. Hoppentocht (Groningen, Netherlands)

    Objective: The primary objective was to determine the comparative bioavailability between a marketed and a new levodopa dry powder inhaler (DPI) with an enhanced usability…
  • 2024 International Congress

    Pregnancy in Parkinson’s disease: Five cases

    C. Armas, Y. Núñez, G. Gushiken, C. Cosentino (Lima, Peru)

    Objective: To report additional cases to the literature of Parkinson’s disease (PD) and pregnant. Background: Pregnancy in PD is a relatively rare occurrence as PD…
  • 2024 International Congress

    Exploring Retrospectively the Predisposing Factors of Sleep Disorders in Parkinson’s Disease.

    SF. Arechavala Lopez, I. Fuentes Calvo, AJ. Hernández-Medrano, A. Cervantes-Arriaga, M. Rodríguez-Violante (CDMX, Mexico)

    Objective: Identify the predisposing or exacerbating factors of sleep disorders in Parkinson's disease, and examine their association with levodopa treatment. Background: Parkinson's disease (PD) is…
  • 2024 International Congress

    Treatment Patterns With Long-Term Foslevodopa/Foscarbidopa Use in Parkinson’s Disease

    J. Aldred, T. Henriksen, M. Bouchard, J. Martínez-Castrillo, M. Soileau, D. Standaert, L. Bergmann, R. Gupta, P. Kukreja, M. Shah, S. Isaacson (Spokane, USA)

    Objective: To assess long-term treatment switch patterns and discontinuation rates in patients (pts) with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDp/CDp) mono- or combination therapy.…
  • 2024 International Congress

    Effects of GBA mutations in patients with Parkinson’s disease and Levodopa-carbidopa intestinal gel: a nation-wide longitudinal multicentre ‘real-world’ study.

    R. Cilia, F. Colucci, E. Cereda, V. Leta, M. Zibetti, M. Carecchio, S. Bonvegna, G. Calandra-Buonaura, R. Cerroni, R. de Micco, S. Tamburin, L. Magistrelli, F. Lena, M. Mascia, M. Picillo, G. Cossu, M. Marano, C. Leuzzi, C. Comi, A. Zampogna, C. Pellicano, S. Barca, V. Fioravanti, A. Pilotto, R. Zangaglia, M. Avenali, C. Sorbera, F. Di Biasio, F. Arienti, A. Nicoletti, C. Bagella, MC. Malaguti, A. Ranghetti, E. Caputo, D. Alimonti, E. Torre, GD. Oggioni, AE. Elia, N. Golfrè Andreasi, G. Devigili, B. Garavaglia, G. Imbalzano, T. Schirinzi, F. Cavallieri, A. Priori, M. Sessa, F. Tamma, M. Canesi, P. Solla, M. Zappia, A. Di Fonzo, L. Avanzino, A. Quartarone, EM. Valente, C. Pacchetti, A. Padovani, F. Valzania, A. Suppa, MT. Pellecchia, N. Modugno, M. Tinazzi, A. Tessitore, A. Stefani, P. Cortelli, IU. Isaias, A. Antonini, MC. Sensi, L. Lopiano, R. Eleopra (Milan, Italy)

    Objective: To investigate the safety and efficacy of LCIG in PD, focusing on the effects of GBA status. Background: Parkinson's disease carriers of GBA mutations/variants…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley